Biotech Values

[lgonber]

CLDN: Hello PGS, I recently learned about your blog and read the posts you have on CLDN there. Thanks for the work. I am currently investor in CLDN. We are next to data and I would like to ask you what is your take on the pps after data release, balancing all the info you currently have, not only scientific, but also after heard the latest CEO call, the latest analysts ratings, the shelf offering...
Also, as you mentioned,
CUPID clinical trial demonstrated a benefit for the 1x10E13 viral genome high dose group versus placebo, it is reasonable to ask, given the low level of persistence of the AAV-SERCA construct and scant data for increased SERCA protein expression, I believe, at that has been proved in the clinic, it is not fair to go back to animal models, it seems difficult for me to admit there was fortuitous coincidence in stead of admitting that in Humans, the functional outcomes are a result of AAV-mediated increases in myocardial SERCA expression.